Development and supply of safe and effective vaccine for global public health

Carrier protein


rCRM197 is a carrier protein produced from genetically modified E. coli (Patent# 10-2099342) and has demonstrated non-inferiority to the natural form made from diphtheria toxoid CRM197. Provided that multiple antigens are not chemically linked to the protein, they have lower immunogenicity for pediatric use, therefore, they’re developed as conjugate vaccines. The protein in conjugate vaccines is referred as a carrier protein.
CRM197 is commonly used as a carrier protein in protein-polysaccharide conjugation, and CRM197 has many advantages over other carrier proteins, i.e. diphtheria toxoid or tetanus toxoid proteins. Our rCRM197 can be mass-produced from genetically modified E. coli at higher yield. It is currently used for the development of Typhoid Conjugate Vaccine (TCV), Meningococcal Conjugate Vaccine (MCV), and Pneumococcal Conjugate Vaccine (PCV) under development.
Product Name rCRM197
Product Purpose For research purpose and at GMP grade for vaccine development
Usage Carrier protein enhancing the immunogenicity
Price $200/mg
Patent 1) Method for Production of rCRM197 by recombinant E.coil (Patent No.:10-2048456)
2) Expression Method of CRM197 Protein (Patent No.:10-2142255)
Research Paper 1) Production of Carrier Protein rCRM197 Using Recombinant E.coli
2) An open-label, comparative, single dose, clinical Phase I study to assess the safety and immunogenicity of typhoid conjugate vaccine(Vi-CRM197)in healthy Filipino adults
3) Generation of a human monoclonal antibody to cross-reactive material 197 (CRM197) and development of a sandwich ELISA for CRM197 conjugate vaccines
Immune-Enhancing Carrier protein, rCRM197

Product Components

Escherichia coli

Product Information

Packaging unit To save Validity Purity
0.5 mg/vial, 1.0 mg/vial
We can customize the product to customer's requirments
2 ~ 8℃ 12 months from manufacturing date above 95%

Please contact if you have any questions about purchasing products.